QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2030-11-07
Target enrollment:
Participant gender:
Summary
This study will look at the efficacy and safety of QL1706 plus albumin-bound paclitaxel and carboplatin in a neoadjuvant setting, in high-risk, TNBC early breast cancer.